Miromatrix Reports Promising Results and Advances in Bioengineering Fully Transplantable Organs

Miromatrix Medical Inc. has released a corporate update along with their 2022 financial report. The company’s primary objective for the year ahead is the initiation of a Phase 1 clinical trial for miroliverELAP. This new bioengineered organ technology, which is focused on providing patients with acute liver failure access to fully transplantable organs, is a significant milestone that, once achieved, will provide vital validation. The company is also concentrating the majority of its resources on miroliverELAP™ to achieve the clearance for IND (investigational new drug) to enable testing by the end of 2023.

Miromatrix has a collaborative research agreement with Baxter International Inc. relating to miroliverELAP™, which it announced on February 1, 2023. miroliverELAP™ is a liver therapy which combines Miromatrix’ single-use bioengineered liver with Baxter’s PrisMax system. The Phase I clinical trial will look to treat patients suffering from acute liver failure. The company has also revealed that presentations have been selected for the American Transplant Congress in June 2023, which will relate to mirokidney and miroliverELAP™.

Miromatrix Medical is making significant progress in bioengineering fully transplantable human organs to address the shortage of available organs. The company’s focus on miroliverELAP™ and the initiation of a Phase 1 clinical trial for this technology is a major milestone that will provide validation for its bioengineering technology platform.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Recent Posts